---
title: Estimation of treatment effects in early-phase randomized clinical trials involving
  external control data
date: '2023-10-12'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37823377/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231012180840&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: There are good reasons to perform a randomized controlled trial (RCT)
  even in early phases of clinical development. However, the low sample sizes in those
  settings lead to high variability of the treatment effect estimate. The variability
  could be reduced by adding external control data if available. For the common setting
  of suitable subject-level control group data only available from one external (clinical
  trial or real-world) data source, we evaluate different analysis options for ...
disable_comments: true
---
There are good reasons to perform a randomized controlled trial (RCT) even in early phases of clinical development. However, the low sample sizes in those settings lead to high variability of the treatment effect estimate. The variability could be reduced by adding external control data if available. For the common setting of suitable subject-level control group data only available from one external (clinical trial or real-world) data source, we evaluate different analysis options for ...